Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
As part of a financing of the Dutch Naional Growth Fund the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative has been granted €325m to speed up the development of cancer drug candidates. As part of the initiative, Leiden-based Mimentas BV will develop patient-specific 3D cancer organoid models that include immune cells, blood vessels, and other cell types for cancer drug and target hogh throughput screening. The company’s automatic phenotypic screening lines with AI data interpretation is aimed at bringing early validation and de-risking to the cancer drug development pipeline.
The goal of Oncode-PACT, which includes 40 partners is to create a state-of-the-art drug development infrastructure to innovate the cancer drug development process. Oncode-PACT is coordinated by the Oncode Institute, a translational research cluster launched in 2017 and funded by the Dutch Cancer Society, the Dutch Research Council (NWO) ZonMW, Health-Holland and the Ministry of Economic Affairs and Climate Policy, the Ministry of Education, Culture and Science and the Ministry of Health, Welfare and Sports.